EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.
EGFR mutations have been shown to correlate with the clinical responsiveness to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The detection of EGFR mutations in non-small cell lung cancer (NSCLC) is important from the perspective of targeted anticancer therapy. We report the first case showing that the status of EGFR mutations can be successfully determined in malignant pleural effusion of NSCLC using polymerase chain reaction (PCR) technique, and correlated to the clinical responsiveness to gefitinib, an EGFR-TKI. This case demonstrated the importance of molecular cytology in the era of targeted therapy.
Huang
Ming-Jer
MJ
Division of Hematology and Oncology, Department of Internal Medicine, Mackay Memorial Hospital, CMU, Taipei, Taiwan.
Lim
Ken-Hong
KH
Tzen
Chin-Yuan
CY
Hsu
Han-Shui
HS
Yen
Yun
Y
Huang
Biing-Shiun
BS
D000970:Antineoplastic Agents / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D000077156:Gefitinib; D017353:Gene Deletion; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016066:Pleural Effusion, Malignant / Q000235:genetics*; D016133:Polymerase Chain Reaction; D049268:Positron-Emission Tomography; D011799:Quinazolines / Q000494:pharmacology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib